Morgan Stanley
CAI icon

Morgan Stanley’s Caris Life Sciences CAI Stock Holding History

Morgan Stanley’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.5M Buy
1,935,531
+856,114
+79% +$15.3M ﹤0.01% 2580
2026
Q1 		$19.3M Sell
1,079,417
-715,574
-40% -$15.6M ﹤0.01% 2995
2025
Q4 		$48.4M Buy
1,794,991
+260,568
+17% +$7.34M ﹤0.01% 2110
2025
Q3 		$46.4M Buy
1,534,423
+729,183
+91% +$23.3M ﹤0.01% 2073
2025
Q2 		$21.5M Buy
+805,240
New +$21.7M ﹤0.01% 2734

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley's CAI Position: Q2 2026 in Review

Morgan Stanley increased its Caris Life Sciences (CAI) stake by 79% in Q2 2026, buying an estimated $15.3M and bringing the position to 1,935,531 shares worth $34.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2580.

Morgan Stanley first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. The position peaked at $48.4M in Q4 2025. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Morgan Stanley held 1,935,531 shares of Caris Life Sciences worth $34.5M as of Q2 2026.
  • Morgan Stanley bought 856,114 Caris Life Sciences shares in Q2 2026, an estimated $15.3M.
  • Caris Life Sciences made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2580 holding.
  • Morgan Stanley first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • Morgan Stanley's Caris Life Sciences position peaked at $48.4M in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.